Overview
Catheter-related bloodstream infections (CRBSIs) are a leading cause of hospital-acquired infections worldwide. Our auranofin-releasing antibacterial and antibiofilm polyurethane catheter coating kills bacteria and prevents them from forming hard-to-eliminate biofilms.
Market Opportunity
Innovation and Meaningful Advantages
We have invented an auranofin-releasing antibacterial and antibiofilm polyurethane catheter coating. Auranofin is an antirheumatic drug with recently identified antimicrobial properties. The coating kills bacteria and prevents them from forming hard-to-eliminate biofilms. The polyurethane drug carrier surrounding the auranofin extends the period of drug-release to up to 28 days, improving its long-term antibacterial and antibiofilm effectiveness, and potentially how long the catheter can remain implanted. The coating is highly stretchable, which is important when used on a flexible catheter. Importantly, the coating also provides a method for treating catheter-related bloodstream infections, such as one resulting from previous catheter insertion.
Collaboration Opportunity
We are interested in exploring 1) startup opportunities with investors in the medical device space; 2) research collaborations with leading medical device companies; and 3) licensing opportunities with medical device companies.
Principal Investigator
IP Information
US Utility US 2020-0297898 A1, Published September 4, 2020
Publication
Liu H, Shukla S, Vera-González N, et al. Auranofin Releasing Antibacterial and Antibiofilm Polyurethane Intravascular Catheter Coatings. Front Cell Infect Microbiol. 2019;9:37. Published 2019 Feb 28. doi:10.3389/fcimb.2019.00037
Contact